Final Program

SUNDAY • MAY 15 29
9:24 Integrated Approaches to Understanding Pulmonary Fibrosis
D.A. Schwartz, MD, Aurora, CO
9:48 What Gene Expression Networks Tell Us About the
Mechanisms of Anti-Inflammatory Glucocorticoid Action
R. Newton, PhD, Calgary, Canada
10:12 DUSP1 and TTP Co-Operate to Regulate Cytokine Expression:
Knowledge Gained from Experimental Models of Arthritis
A.R. Clark, PhD, Birmingham, United Kingdom
10:36 RNA-Protein Interactions on a Global Scale: Investigating
mRNA-Binding Proteomes in Model Organisms
A.P. Gerber, PhD, Guildford, United Kingdom
This session and the International Conference are supported by an educational grant from
Boehringer Ingelheim Pharmaceuticals, Inc.
All CME sessions have been planned and implemented in accordance with the Essential
Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME)
and are free of the control of commercial interests.
A6
BASIC • CLINICAL • TRANSLATIONAL
SCIENTIFIC SYMPOSIUM
CME Credits Available: 2.0
JOINT ATS/ERS/JRS SYMPOSIUM ON SEVERE
ASTHMA: A GLOBAL PERSPECTIVE
Assemblies on Allergy, Immunology and Inflammation; Clinical
Problems; Environmental, Occupational and Population Health; Nursing;
Pediatrics; Respiratory Cell and Molecular Biology; Respiratory
Structure and Function
9:00 a.m. - 11:00 a.m. MOSCONE CENTER
Room 2001/2003 (West Building, Level 2)
Target Audience
Providers of lung health and those taking care of patients with asthma.
Objectives
At the conclusion of this session, the participant will be able to:
• review recent advances in the epidemiology and molecular basis of severe
asthma;
• understand the clinical and molecular heterogeneity of severe asthma;
• highlight areas of needed research to reduce the impact of this disease on
human health.
This symposium proposal represents an international collaborative effort between
members of the Japanese Respiratory Society, The European Respiratory Society,
and the American Thoracic Society to foster interactions towards a precision
medicine approach to severe asthma. Globally, severe asthma represents a subset
of asthma accounting for approximately 5-10% of patients with asthma. However
health care utilization for this subset has been estimated to be up to 40% of the
economic burned of asthma. Recently there has been significant efforts to determine
the underlying basis for this disease in terms of epidemiology, physiology,
immunology, and genetics that influence this phenotype. Data are emerging that
serve asthma consists of several endotypes. This phenotypic and now molecular
classification may greatly aid in patient management with improved disease control,
improved clinical outcomes and reduced medical costs. This symposium will
highlight recent advances as well as highlight needed areas of research to advance
treatment and prevention of this disease.
Chairing: G.P. Downey, MD, Denver, CO
K. Asano, MD, Kanagawa, Japan
S. Hashimoto, MD, Tokyo, Japan
B.D. Levy, MD, Boston, MA
N.N. Jarjour, MD, Madison, WI
9:00 Introduction and Overview of Severe Asthma
B.D. Levy, MD, Boston, MA
9:05 Severe Asthma: Lessons Learned from Global Studies
K. Asano, MD, Kanagawa, Japan
9:22 Severe Asthma in the Pediatric Population
S.J. Szefler, MD, Aurora, CO
9:39 Pathogenesis of Severe Asthma: A Clue from the Common
Genes Underlying Asthma and COPD
N. Hizawa, MD, Tsukuba, Japan
9:56 Serum Periostin: A Key Marker to Dissect the Pathophysiology
of Type 2-Predominant Asthma
H. Matsumoto, MD, PhD, Kyoto, Japan
10:14 Current Therapies for Severe Asthma in 2016
M. Kraft, MD, Tucson, AZ
Parker B. Francis Speaker
10:32 Severe Asthma Phenotype/Endotype Guided Therapy
P.J. Sterk, MD, PhD, Amsterdam, Netherlands
10:50 Summary of Symposium and Panel Discussion
N.N. Jarjour, MD, Madison, WI
This session and the International Conference are supported by an educational grant from
AstraZeneca LP.
All CME sessions have been planned and implemented in accordance with the Essential
Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME)
and are free of the control of commercial interests.
A7
BASIC • CLINICAL • TRANSLATIONAL
SCIENTIFIC SYMPOSIUM
CME Credits Available: 2.0
ATS MYTHBUSTER: REVERSING FIBROSIS IN THE
LUNGS IS BIOLOGICAL MISSION (IM)POSSIBLE
Assemblies on Respiratory Cell and Molecular Biology; Allergy,
Immunology and Inflammation; Clinical Problems; Respiratory Structure
and Function
9:00 a.m. - 11:00 a.m. MOSCONE CENTER
Room 2016/2018 (West Building, Level 2)
Target Audience
Basic, translational, clinical researchers, and clinicians interested in fibrotic
lung diseases, including IPF, connective tissue disease-ILD, chronic
hypersensitivity pneumonitis and sarcoidosis.
Objectives
At the conclusion of this session, the participant will be able to:
• understand both the overall potential, and the current barriers, to reverse
established fibrosis in patients with fibrotic lung diseases;
• understand how effector fibroblasts and extracellular matrix could be targeted to
induce the regression of established fibrosis;
SUNDAY MORNING
ATS 2016 • San Francisco